Protocol Ledger

NCT05814666 · Phase II · TERMINATED

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Interventional Phase II clinical trial protocol NCT05814666 sponsored by Flamingo Therapeutics NV in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-30 Enrollment: 69 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05814666
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)69 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05814666
Protocol FieldVerified Registry Value
NCT IdentifierNCT05814666
Consolidated Lead SponsorFlamingo Therapeutics NV
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment69 participants (ACTUAL)
Registered Start Date2023-05-30
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI